Skip to main content

Table 4 QT and PR prolongation

From: Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review

Author, year

Treatment (dose, time of treatment)

Hesketh [18]

   
 

Dolasetron (1.2 mg/kg, BC)

Dolasetron (1.8 mg/kg, BC)

Dolasetron (2.4 mg/kg, BC)

QT prolongation*

11 ms

27 ms

39 ms

PR prolongation

1 ms

10 ms

22 ms

Gralla [19]

   
 

Palonosetron (0.25 mg, BC)

Palonosetron (0.75 mg, BC)

Ondansetron (32 mg, BC)

QT prolongation*

1 ms

2 ms

5 ms

PR prolongation

NS

NS

NS

Kim [20]

   
 

Dolasetron (100, BC+ 800 mg, AC)

Ondansetron (8 mg, BC + 80 mg, AC)

 

QT prolongation

NS

NS

 

PR prolongation

NS

NS

 
  1. AC: after chemotherapy treatment; BC: before the start of chemotherapy treatment; NS: not significant. *mean change from baseline; median change from baseline.